ACARBOSE Drug Patent Profile

When do Acarbose patents expire, and what generic alternatives are available?

Acarbose is a drug marketed by Avet Lifesciences, Hangzhou Zhongmei, Hikma, Impax Labs, Natco Pharma Usa, Somerset Theraps Llc, Strides Pharma, and Watson Labs. and is included in eight NDAs.

The generic ingredient in ACARBOSE is acarbose. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acarbose profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Acarbose

A generic version of ACARBOSE was approved as acarbose by HIKMA on May 7^th, 2008.

Summary for ACARBOSE

US Patents:	0
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	98
Patent Applications:	24
Drug Prices:	Drug price information for ACARBOSE
What excipients (inactive ingredients) are in ACARBOSE?	ACARBOSE excipients list
DailyMed Link:	ACARBOSE at DailyMed

See drug prices for ACARBOSE

Recent Clinical Trials for ACARBOSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Changzhou No.2 People's Hospital	PHASE4
Xiangya Hospital of Central South University	PHASE4
Jiangsu Province Hospital of Traditional Chinese Medicine	PHASE4

See all ACARBOSE clinical trials

Pharmacology for ACARBOSE

Drug Class	alpha-Glucosidase Inhibitor
Mechanism of Action	alpha Glucosidase Inhibitors

Medical Subject Heading (MeSH) Categories for ACARBOSE

Glycoside Hydrolase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ACARBOSE

A10BF	Alpha glucosidase inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for ACARBOSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRECOSE	Tablets	acarbose	25 mg, 50 mg and 100 mg	020482	1	2005-03-22

US Patents and Regulatory Information for ACARBOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avet Lifesciences	ACARBOSE	acarbose	TABLET;ORAL	202271-001	Feb 7, 2012	AB	RX	No	No
Somerset Theraps Llc	ACARBOSE	acarbose	TABLET;ORAL	091343-003	Oct 17, 2013	AB	RX	No	No
Watson Labs	ACARBOSE	acarbose	TABLET;ORAL	077532-003	May 7, 2008	AB	RX	No	No
Hikma	ACARBOSE	acarbose	TABLET;ORAL	078470-001	May 7, 2008	AB	RX	No	No
Hangzhou Zhongmei	ACARBOSE	acarbose	TABLET;ORAL	213821-001	Aug 18, 2020		DISCN	No	No
Impax Labs	ACARBOSE	acarbose	TABLET;ORAL	078441-003	May 14, 2009	AB	RX	No	No
Strides Pharma	ACARBOSE	acarbose	TABLET;ORAL	090912-002	Jul 27, 2011	AB	RX	No	No

Market Dynamics and Financial Trajectory for Acarbose

Last updated: April 6, 2026

Acarbose, an alpha-glucosidase inhibitor, is used primarily for managing type 2 diabetes mellitus. It inhibits carbohydrate absorption in the gut, reducing postprandial hyperglycemia. The drug's market is influenced by evolving diabetes treatment paradigms, regulatory policies, and regional healthcare landscapes.

Market Overview

Globally, the acarbose market was valued at approximately USD 150 million in 2022. Projected compound annual growth rate (CAGR) from 2023 to 2030 is estimated at 4.5%. Growth is driven by increasing type 2 diabetes prevalence, especially in emerging markets.

Key Regions

• Asia-Pacific: Holds the largest market share (~60%) due to higher diabetes prevalence rates, especially in China and India. Governments promote affordable treatment options.
• North America: Accounts for roughly 20% of the market; growth driven by aging population and brand diversification.
• Europe: Represents about 10%; growth influenced by healthcare policies favoring oral antidiabetics over injectable therapies.

Competitive Landscape

Major players include:

• Bayer AG: Produces Precose (acarbose). Holds significant market share owing to established branding.
• Shenzhen Salubris Pharmaceuticals: Marketing generic versions; expanding in Asian markets.
• MSD (Merck & Co.): Investigates novel formulations to extend patent life and improve efficacy.

Market Drivers

Rising prevalence of type 2 diabetes. The International Diabetes Federation reports over 537 million adults diagnosed globally in 2021, projected to reach 643 million by 2030.
Cost-effectiveness of acarbose. It offers an affordable alternative to newer, more expensive therapies, appealing in resource-constrained regions.
Preference for oral medications. Patients favor non-injectable options, fostering demand for acarbose, especially in countries with limited healthcare infrastructure.

Regulatory and Policy Factors

Patent expirations: Several patents on branded acarbose products expired between 2018-2022, leading to increased generic competition.
Regulatory approvals: Some regional regulators, such as the China Food and Drug Administration (CFDA), have approved long-acting formulations to improve compliance.
Reimbursement policies: Differ across markets; in some regions, inclusion in national formularies enhances sales volume.

Financial Trajectory

Revenue Trends

Year	Estimated Revenue (USD millions)
2022	150
2023	157
2024	165
2026	185
2030	210

The growth trajectory assumes a steady increase, tempered by generic entry and patent cliff effects.

R&D and Investment Outlook

• R&D investments focus on combination therapies (e.g., acarbose with SGLT2 inhibitors).
• Biotech firms explore modified-release formulations to improve efficacy and tolerability.
• Major companies may allocate USD 20-50 million annually for formulation innovation between 2023-2026.

Risks and Challenges

• Market saturation: Many competitors and emerging therapies (e.g., GLP-1 receptor agonists) threaten market share.
• Side effect profile: Gastrointestinal adverse effects may limit adherence.
• Evolving treatment protocols: Increased use of injectable therapies could diminish oral medication demand.

Future Outlook

The future of acarbose relies on:

• Formulation enhancements to improve tolerability and compliance.
• Strategic positioning in combination regimens.
• Regional expansion, with a focus on Asia-Pacific and Africa.
• Regulatory policies supporting generic availability and affordable pricing.

Key Takeaways

• The acarbose market faced USD 150 million valuation in 2022, with a CAGR of 4.5% projected through 2030.
• Expansion hinges on diabetic prevalence, cost advantages, and formulation innovations.
• Patent expiries have increased generic competition, impacting margins.
• Growth opportunities exist in combination therapies and emerging markets.
• Market risks include increased competition from injectable drugs and adverse effects limiting adherence.

FAQs

1. What factors influence acarbose's market growth?
Prevalence of type 2 diabetes, healthcare policies favoring oral treatment, and affordability in developing regions.

2. How does patent expiration impact acarbose sales?
Patent loss allows generic manufacturers to enter, increasing competition and reducing prices, potentially decreasing revenues for branded products.

3. What are the main challenges faced by acarbose?
Gastrointestinal side effects, competition from newer therapies, and regional regulatory barriers.

4. Which regions offer the largest growth potential?
Asia-Pacific, and to a lesser extent, Africa, due to rising diabetes rates and demand for affordable treatments.

5. How are companies innovating within the acarbose market?
Developing long-acting formulations, combination therapies, and improving tolerability.

---

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas.
[2] MarketWatch. (2023). Global Acarbose Market Size, Share & Trends.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals and Labeling.
[4] European Medicines Agency. (2021). Annual Report on Diabetes Medications.
[5] World Health Organization. (2022). Diabetes Fact Sheet.

DrugChatter Q&A for ACARBOSE

Acarbose biosynthesis u's patent application?
Acarbose biosynthesis u's patent application?
Acarbose biosynthesis patent?
Patent acarbose biosynthesis?
Us patent 12351847 acarbose?